Home Neoplasma 2016 Neoplasma Vol.63, No.3, p.333-341,2016

Journal info

6 times a year.
Founded: 1954
ISSN 0028-2685
ISSN 1338-4317 (online)

Published in English

Editorial Info
Abstracted and Indexed
Submission Guidelines

Select Journal

Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Neoplasma Vol.63, No.3, p.333-341,2016

Title: Current trends in the treatment of malignant melanoma

Abstract: Currently, skin cancer is one of the most frequent type of cancers. Melanoma is much less common than basal cell and squamous cell skin cancers, but it is far more dangerous. Melanomas represent 3% of all skin cancers but 65% of skin cancer deaths. Detailed knowledge of melanoma at the molecular level allows the development of new treatment alternatives and to design effective new drugs. There are two approaches in therapy of melanoma in the present is based on immunotherapy and targeted therapy or their combination. Immunotherapy includes immune checkpoint blockades whereas targeted therapy is represented by protein kinase inhibitors. Detailed knowledge of protein structure and the understanding of their role in key signalling pathways in melanoma development lead to the designation of new protein kinase inhibitors in targeted therapy. In the future, it is necessary to conduct further clinical trials and collect more data about overall survival, response rates, appropriate timing and sequence of combination therapy to manage the complexity of melanoma treatment.

Keywords: melanoma, immunotherapy, targeted therapy, protein kinase inhibitors
Published online: 16-May-2016
Year: 2016, Volume: 63, Issue: 3 Page From: 333, Page To: 341

download file

© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.